



SAVE THE DATE
7th May 2023



**MALAYSIAN
THORACIC
SOCIETY**

**Event code
CPDE45379**

International Respiratory Leadership Forum

We are delighted to invite you to the virtual **International Respiratory Leadership Forum** on the 7th May 2023. The meeting will focus on the characterizations of severe asthma patients as well as unleash key findings from the largest severe asthma data of more than 17,000 patients from the ISAR international registry which will be presented by Prof. David Price, the founder, and head of OPC (Optimum Patient Care, UK and Australia). The second half will look into great details of making sense of the inflammatory biomarkers in severe asthma, which will be covered by Prof. David Jackson, the renowned pulmonologist behind the state of art severe asthma center (Guys and St Thomas, UK).

**Date
&
Time**



Saturday 7th May 2023

**9:00 am - 10:30 am GMT 12:00 pm - 1:30 pm UAE /
4:00 pm - 5:30 pm Malaysia**

Speakers:

[Click Here to Register](#)



Prof. David Price (Australia)

Professor David Price is founder and head of Optimum Patient Care (UK and Australia), a science-based, social enterprise which focuses on disease registries and supporting care in primary and secondary care led by internationally recognised experts in all areas of respiratory medicine. He is also the founder of The Observational and Pragmatic Research Institute (Singapore), an independent, research-driven organisation established to cultivate initiatives, provide evidence and drive quality standards within the growing field of real-life, pragmatic and observational research. This dynamic organisation delivers pragmatic clinical trials and real-life database research across multiple geographies, including territories in the United States, Europe and the Asia-Pacific region.



Prof. David Jackson (United Kingdom)

David Jackson is Professor of Respiratory Medicine at King's College London and Head of the regional Severe Asthma and Eosinophilic Lung Disease Service at Guy's and St Thomas' Hospitals in London. This unit is the largest of its kind in the UK and currently cares for over 1000 patients on biologic therapies for asthma and EGPA. Professor Jackson has published widely in the field of type 2 immunity, biologic therapies in asthma, and the mechanisms of virus-induced asthma exacerbations and is the chief investigator on several clinical trials of biologic therapies in asthma and EGPA. He is an Associate Editor at the journals THORAX and ALLERGY, a Reviews Editor at CHEST, and co-edited the ERS Monograph on Eosinophilic Lung Diseases.

Agenda:

TOPICS	SPEAKERS	TIME
Opening and Introduction	Hisham Farouk (AstraZeneca)	
Characterization of Severe Asthma patients and Key findings from the largest Severe Asthma registry: ISAR	Prof. David Price (Australia)	30mins
Q&A		15mins
Making sense of the T2 biomarkers to guide OCS stewardship & targeted therapy	Prof. David Jackson (UK)	30mins
Q&A		15mins
Closing	Sachin Joshi (AstraZeneca)	

This webinar is intended for registered healthcare professionals only.
This meeting focuses on the topics of respiratory and immunology. RSVP is required.
For more information please contact Kishen Sivakumar (+0162119452)

MY-11187_APR2023

AstraZeneca

AstraZeneca Sdn Bhd (69730-X)
The Bousteador, Level 12, No. 10, Jalan PJU 7/6,
Mutiar Damansara, 47800 Petaling Jaya, Selangor, Malaysia